-
Je něco špatně v tomto záznamu ?
CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase
M. Hernández-Sánchez, J. Kotaskova, AE. Rodríguez, L. Radova, D. Tamborero, M. Abáigar, K. Plevova, R. Benito, N. Tom, M. Quijada-Álamo, V. Bikos, AÁ. Martín, K. Pal, A. García de Coca, M. Doubek, N. López-Bigas, JM. Hernández-Rivas, S. Pospisilova,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural
Perzistentní odkaz
https://www.medvik.cz/link/bmc19028215
Grantová podpora
U10 CA180888
NCI NIH HHS - United States
U10 CA180819
NCI NIH HHS - United States
Online
Plný text
NLK
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Nursing & Allied Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- chromozomální aberace * MeSH
- chronická lymfatická leukemie genetika patologie terapie MeSH
- kombinovaná terapie MeSH
- lidé MeSH
- longitudinální studie MeSH
- mutace * MeSH
- nádorové biomarkery genetika MeSH
- následné studie MeSH
- prognóza MeSH
- sekvenování exomu MeSH
- studie případů a kontrol MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Research Support, N.I.H., Extramural MeSH
Hematology Department Hospital Clínico Universitario of Valladolid Valladolid Spain
Hematology Department Hospital Universitario Salamanca Salamanca Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028215
- 003
- CZ-PrNML
- 005
- 20190819091103.0
- 007
- ta
- 008
- 190813s2019 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-018-0255-1 $2 doi
- 035 __
- $a (PubMed)30209402
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Hernández-Sánchez, María $u Hematology Department, Hospital Universitario Salamanca, Salamanca, Spain. IBSAL, IBMCC-Cancer Research Center, University of Salamanca, Salamanca, Spain.
- 245 10
- $a CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase / $c M. Hernández-Sánchez, J. Kotaskova, AE. Rodríguez, L. Radova, D. Tamborero, M. Abáigar, K. Plevova, R. Benito, N. Tom, M. Quijada-Álamo, V. Bikos, AÁ. Martín, K. Pal, A. García de Coca, M. Doubek, N. López-Bigas, JM. Hernández-Rivas, S. Pospisilova,
- 650 _2
- $a nádorové biomarkery $x genetika $7 D014408
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 12
- $a chromozomální aberace $7 D002869
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a chronická lymfatická leukemie $x genetika $x patologie $x terapie $7 D015451
- 650 _2
- $a longitudinální studie $7 D008137
- 650 12
- $a mutace $7 D009154
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a sekvenování exomu $7 D000073359
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 700 1_
- $a Kotaskova, Jana $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Center of Molecular Biology and Gene Therapy, Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Rodríguez, Ana E $u Hematology Department, Hospital Universitario Salamanca, Salamanca, Spain. IBSAL, IBMCC-Cancer Research Center, University of Salamanca, Salamanca, Spain.
- 700 1_
- $a Radova, Lenka $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Tamborero, David $u Research Programon Biomedical Informatics, IMIM Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Barcelona, Spain. Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain.
- 700 1_
- $a Abáigar, María $u Hematology Department, Hospital Universitario Salamanca, Salamanca, Spain. IBSAL, IBMCC-Cancer Research Center, University of Salamanca, Salamanca, Spain.
- 700 1_
- $a Plevova, Karla $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Center of Molecular Biology and Gene Therapy, Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Benito, Rocío $u Hematology Department, Hospital Universitario Salamanca, Salamanca, Spain. IBSAL, IBMCC-Cancer Research Center, University of Salamanca, Salamanca, Spain.
- 700 1_
- $a Tom, Nikola $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Quijada-Álamo, Miguel $u Hematology Department, Hospital Universitario Salamanca, Salamanca, Spain. IBSAL, IBMCC-Cancer Research Center, University of Salamanca, Salamanca, Spain.
- 700 1_
- $a Bikos, Vasileos $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Martín, Ana África $u Hematology Department, Hospital Universitario Salamanca, Salamanca, Spain.
- 700 1_
- $a Pal, Karol $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a García de Coca, Alfonso $u Hematology Department, Hospital Clínico Universitario of Valladolid, Valladolid, Spain.
- 700 1_
- $a Doubek, Michael $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Center of Molecular Biology and Gene Therapy, Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a López-Bigas, Nuria $u Research Programon Biomedical Informatics, IMIM Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Barcelona, Spain. Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain.
- 700 1_
- $a Hernández-Rivas, Jesús-María $u Hematology Department, Hospital Universitario Salamanca, Salamanca, Spain. jmhr@usal.es. IBSAL, IBMCC-Cancer Research Center, University of Salamanca, Salamanca, Spain. jmhr@usal.es.
- 700 1_
- $a Pospisilova, Sarka $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. pospisilova.sarka@fnbrno.cz. Center of Molecular Biology and Gene Therapy, Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic. pospisilova.sarka@fnbrno.cz.
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 33, č. 2 (2019), s. 518-558
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30209402 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190819091337 $b ABA008
- 999 __
- $a ok $b bmc $g 1433364 $s 1066675
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 33 $c 2 $d 518-558 $e 20180912 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- GRA __
- $a U10 CA180888 $p NCI NIH HHS $2 United States
- GRA __
- $a U10 CA180819 $p NCI NIH HHS $2 United States
- LZP __
- $a Pubmed-20190813
